A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
Recruiting now Phase 3 NCT07219420
Run by UCB Biopharma SRL · for 18 and older · All sexes
What this study is about
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
Who can join (things the study team will check)
✅ You may be able to join if…
- At least 18 years of age inclusive, at the time of signing the informed consent form (ICF)
- Have a palmoplantar pustulosis (PPP) diagnosis for at least 24 weeks prior to the Screening Visit
- Have PPPASI ≥12 at the Screening Visit and Baseline Visit
- Have PPP-IGA ≥3 at the Screening Visit and Baseline Visit
- Have pustules on the palms of the hands and/or soles of the feet at the Screening Visit and Baseline Visit, defined as pustule severity ≥2 and having more than 5 active pustules
- Participant must be a candidate for systemic therapy or phototherapy
🚫 You may not be able to join if…
- Has PPP symptoms which improve significantly between the Screening Visit and Baseline Visit, defined as a reduction in the PPPASI score
- Has the following: palmoplantar PSO (plaque PSO on palms/soles), guttate PSO, erythrodermic PSO (EP), generalized pustular PSO (GPP), Acrodermatitis continua of Hallopeau (ACH), atopic dermatitis, dyshidrotic eczema or chronic hand eczema.
- Has drug-induced PSO (eg, first onset or current exacerbation due to beta blockers, calcium channel inhibitors, lithium, or tumor necrosis factor [TNF] inhibitor) or drug-induced pustular PSO (eg, acute generalized exanthematous pustulosis, acute localized exanthematous pustulosis)
- Has cutaneous lesions that may interfere with the evaluation of the affected area and/or evaluation of the severity of PPP
- Is taking or has taken prohibited or restricted medications without meeting the mandatory discontinuation or stability period relative to the Baseline Visit
- Is taking or has ever taken an interleukin (IL)-17A/IL-17F inhibitor, including bimekizumab, or has participated in a bimekizumab investigational study
Where this trial is running
- Ppp001 50754, Birmingham, Alabama, United States
- Ppp001 50746, Coral Gables, Florida, United States
- Ppp001 50757, Auburn Hills, Michigan, United States
- Ppp001 50745, Columbus, Ohio, United States
- Ppp001 50202, Fairborn, Ohio, United States
- Ppp001 50744, Oklahoma City, Oklahoma, United States
- Ppp001 50233, Barrie, Canada
- Ppp001 50354, Calgary, Canada
- Ppp001 50749, Fredericton, Canada
- Ppp001 50765, London, Canada
- Ppp001 50740, Québec, Canada
- Ppp001 50752, Red Deer, Canada
+ 73 more sites.
Who to contact
UCB Cares · +18445992273 · ucbcares@ucb.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07219420.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.